Burling Wealth Partners LLC Sells 11,537 Shares of AstraZeneca PLC $AZN

Burling Wealth Partners LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 31.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,736 shares of the company’s stock after selling 11,537 shares during the period. Burling Wealth Partners LLC’s holdings in AstraZeneca were worth $1,974,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. NewSquare Capital LLC lifted its stake in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after acquiring an additional 218 shares during the last quarter. Rakuten Investment Management Inc. bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $31,000. FSA Wealth Management LLC lifted its stake in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares during the last quarter. VSM Wealth Advisory LLC bought a new position in AstraZeneca during the second quarter worth about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AZN shares. HSBC reaffirmed a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Finally, Citigroup initiated coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Price Performance

NASDAQ:AZN opened at $208.47 on Thursday. AstraZeneca PLC has a 52 week low of $122.48 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The firm’s 50-day simple moving average is $119.74 and its 200 day simple moving average is $95.74. The firm has a market cap of $323.32 billion, a price-to-earnings ratio of 69.26, a P/E/G ratio of 1.59 and a beta of 0.34.

AstraZeneca Announces Dividend

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be paid a $1.595 dividend. This represents a dividend yield of 165.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s payout ratio is 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.